GCR quotes David Hull on the EU rare excessive pricing investigation in the pharmaceutical sector
- 15/05/2017
- News
On 15 May 2017, Van Bael & Bellis Partner David Hull was quoted in a GCR article on the EU formal investigation into Aspen following concerns that the drug maker has unjustifiably increased the price of several anti-cancer medications, marking the enforcer’s first excessive pricing case in the pharmaceutical sector.
The full article is available here.
